Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) just unveiled an update.
Neurizon Therapeutics has issued 33,212,500 fully paid ordinary shares at $0.08 per share to place the shortfall from its recent entitlement offer. The company states the shares were issued without a prospectus under the Corporations Act, confirms compliance with its continuous disclosure and financial reporting obligations, and notes there is no excluded information as at the date of the notice.
The cleansing statement enables secondary trading of the newly issued shares by confirming regulatory compliance, which supports liquidity for investors following the capital raise. The move strengthens Neurizon’s funding position as it advances its ALS drug candidate NUZ-001, with implications for its ability to sustain clinical development and maintain its profile in the competitive neurodegenerative therapeutics sector.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, targets amyotrophic lateral sclerosis, with a strategy to accelerate patient access to effective ALS therapies while exploring broader neurodegenerative indications through international collaborations and clinical programs.
Average Trading Volume: 560,917
Technical Sentiment Signal: Sell
Current Market Cap: A$63.09M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.